BioCentury
ARTICLE | Clinical News

Urovant shares slide on vibegron overactive bladder data

March 19, 2019 5:23 PM UTC

Despite hitting the co-primary endpoints for an indication in need of treatment options, Urovant's overactive bladder therapy vibegron underwhelmed investors with its latest data on Tuesday by performing only marginally better than the generic comparator in the Phase III EMPOWUR trial. The company lost $2.91 (20%) to $11 on Tuesday.

Urovant Sciences Ltd. (NASDAQ:UROV) plans to submit an NDA to FDA by early 2020 for vibegron to treat overactive bladder...